These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 14187491)

  • 21. Dopamine agonist-mediated rotation in rats with unilateral nigrostriatal lesions is not dependent on net inhibitions of rate in basal ganglia output nuclei.
    Ruskin DN; Bergstrom DA; Mastropietro CW; Twery MJ; Walters JR
    Neuroscience; 1999; 91(3):935-46. PubMed ID: 10391472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin innervation of basal ganglia in monkeys and humans.
    Parent M; Wallman MJ; Gagnon D; Parent A
    J Chem Neuroanat; 2011 Jul; 41(4):256-65. PubMed ID: 21664455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible dopaminergic pathway from substantia nigra to putamen.
    York DH
    Brain Res; 1970 Jun; 20(2):233-49. PubMed ID: 4396620
    [No Abstract]   [Full Text] [Related]  

  • 24. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat.
    Agid Y; Javoy F; Glowinski J
    Nat New Biol; 1973 Oct; 245(144):150-1. PubMed ID: 4517903
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism.
    Delaville C; Navailles S; Benazzouz A
    Neuroscience; 2012 Jan; 202():424-33. PubMed ID: 22138505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic neurons: similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway.
    Walters JR; Roth RH; Aghajanian GK
    J Pharmacol Exp Ther; 1973 Sep; 186(3):630-9. PubMed ID: 4728341
    [No Abstract]   [Full Text] [Related]  

  • 27. Non-dopaminergic nigrostriatal pathway.
    Guyenet PG; Crane JK
    Brain Res; 1981 Jun; 213(2):291-305. PubMed ID: 7248760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substantia nigra control of basal ganglia nuclei.
    Guatteo E; Cucchiaroni ML; Mercuri NB
    J Neural Transm Suppl; 2009; (73):91-101. PubMed ID: 20411770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitation of fiber growth in transplanted central monoamine neurons.
    Seiger A; Olson L
    Cell Tissue Res; 1977 Apr; 179(3):285-316. PubMed ID: 861999
    [No Abstract]   [Full Text] [Related]  

  • 30. Dopamine modulation of the effects of gamma-aminobutyric acid on substantia nigra pars reticulata neurons.
    Waszcak BL; Walters JR
    Science; 1983 Apr; 220(4593):218-21. PubMed ID: 6828891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes of amino acid and monoamine levels after neonatal 6-hydroxydopamine denervation in rat basal ganglia, substantia nigra, and Raphe nuclei.
    Molina-Holgado E; Dewar KM; Grondin L; van Gelder NM; Reader TA
    J Neurosci Res; 1993 Jul; 35(4):409-18. PubMed ID: 8360949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biosynthesis, storage and release of dopamine at the level of the dopaminergic nigro-neostriatal system].
    Glowinski J
    Arch Ital Biol; 1973 Dec; 111(3-4):504-15. PubMed ID: 18847048
    [No Abstract]   [Full Text] [Related]  

  • 33. Light and electron microscopic autoradiography of substantia nigra of rat after intraventricular administration of tritium labelled norepinephrine, dopamine, serotonin and the precursors.
    Parizek J; Hassler R; Bak IJ
    Z Zellforsch Mikrosk Anat; 1971; 115(1):137-48. PubMed ID: 4102158
    [No Abstract]   [Full Text] [Related]  

  • 34. Dopaminergic neurons: reversal of effects elicited by gamma-butyrolactone by stimulation of the nigro-neostriatal pathway.
    Murrin LC; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Oct; 295(1):15-20. PubMed ID: 12482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of risperidone, clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons of the rat brain.
    Bruggeman R; Westerink BH; Timmerman W
    Eur J Pharmacol; 1997 Apr; 324(1):49-56. PubMed ID: 9137912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histofluorescence analysis of several systems of catecholaminergic nerve fibres within the rat neostriatum revealed by either restricted lesions of the substantia nigra or gamma-hydroxybutyrate.
    Arluison M; Javoy-Agid F; Feuerstein C; Tauc M; Conrath-Verrier M; Mailly P
    Brain Res Bull; 1982; 9(1-6):355-65. PubMed ID: 7172034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axoplasmic transport of dopamine in nigro-striatal neurons.
    Fibiger HC; McGeer EG; Atmadja S
    J Neurochem; 1973 Aug; 21(2):373-85. PubMed ID: 4125072
    [No Abstract]   [Full Text] [Related]  

  • 38. Using a novel PV-Cre rat model to characterize pallidonigral cells and their terminations.
    Oh YM; Karube F; Takahashi S; Kobayashi K; Takada M; Uchigashima M; Watanabe M; Nishizawa K; Kobayashi K; Fujiyama F
    Brain Struct Funct; 2017 Jul; 222(5):2359-2378. PubMed ID: 27995326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nigrostriatal dopamine neurons express low levels of GTP cyclohydrolase I protein.
    Hirayama K; Kapatos G
    J Neurochem; 1998 Jan; 70(1):164-70. PubMed ID: 9422359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.